Akoya Biosciences Inc Cash Flow Conversion Efficiency
Akoya Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Akoya Biosciences Inc (AKYA) has a cash flow conversion efficiency ratio of 1.225x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.21 Million) by net assets ($-5.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Akoya Biosciences Inc (2019–2024)
Cash flow conversion efficiency of Akoya Biosciences Inc from 2019 to 2024. This chart illustrates how Akoya Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Akoya Biosciences Inc stock price for real-time trading data and today's change.
Akoya Biosciences Inc Cash Flow Conversion Ratio Explained
Akoya Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Akoya Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akoya Biosciences Inc ranked by their cash flow conversion efficiency. Also see market cap of Akoya Biosciences Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cedergrenska AB
ST:CEDER
|
0.337x |
|
LumenRadio AB
ST:LUMEN
|
0.037x |
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
0.034x |
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
-0.200x |
|
Hoffmann Green Cement Technologies
PA:ALHGR
|
-0.244x |
|
Gentian Diagnostics AS
OL:GENT
|
0.208x |
|
Top High Image
TWO:3284
|
0.004x |
|
HY Energy Group Co Ltd
SHG:600387
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Akoya Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Akoya Biosciences Inc from 2019 to 2024. Review AKYA financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.59 Million | $-44.10 Million | -5.807x | -513.44% |
| 2023-12-31 | $53.77 Million | $-50.90 Million | -0.947x | -3.66% |
| 2022-12-31 | $58.58 Million | $-53.50 Million | -0.913x | -207.25% |
| 2021-12-31 | $121.35 Million | $-36.07 Million | -0.297x | +19.34% |
| 2020-12-31 | $18.57 Million | $-6.84 Million | -0.368x | -180.67% |
| 2019-12-31 | $-30.16 Million | $-13.78 Million | 0.457x | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more